Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

Nicolas Batty, Naveen Yarlagadda, Roberto Pili

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

Original languageEnglish (US)
Pages (from-to)911-915
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number8
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Castration
Prednisone
Cyclophosphamide
Prostatic Neoplasms
docetaxel
Dimethoate
Neoplasm Metastasis
Liver
Drug Therapy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. / Batty, Nicolas; Yarlagadda, Naveen; Pili, Roberto.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. 8, 01.08.2013, p. 911-915.

Research output: Contribution to journalArticle

@article{ac7055add2884f2bbee2f5df9115738d,
title = "Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer",
abstract = "Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.",
author = "Nicolas Batty and Naveen Yarlagadda and Roberto Pili",
year = "2013",
month = "8",
day = "1",
language = "English (US)",
volume = "11",
pages = "911--915",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer

AU - Batty, Nicolas

AU - Yarlagadda, Naveen

AU - Pili, Roberto

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

AB - Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclo-phosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

UR - http://www.scopus.com/inward/record.url?scp=84882995176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882995176&partnerID=8YFLogxK

M3 - Article

C2 - 23946170

AN - SCOPUS:84882995176

VL - 11

SP - 911

EP - 915

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 8

ER -